Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. Molly Heublein

Primary Care · Clear Medical Clinic

View

Dr. Ryan Mire

Primary Care · Heritage Medical Associates

View

Dr. Christopher Chiu

Primary Care · OSU

View

Dr. Matthew Watto

Primary Care · The Curbsiders Internal Medicine Podcast

View

Dr. Joanne Loethen

Primary Care · TMC

View

Dr. Monica Peek

Primary Care · UCMC

View

Dr. Sachin Jain

Primary Care

View

Dr. Bhavna Lall

Primary Care · BWH

View

Dr. Kirsten Bibbins-Domingo

Primary Care · JAMA and JAMA Network

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Antibiotic Use Linked to Worse Outcomes in Patients With Gastrointestinal and Liver Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis.

    Feb 12, 2026DOI: 10.14309/ajg.0000000000003956Journal ArticleACG

    Written by: Mohammad Saeid Rezaee-ZavarehHamidreza Karimi-SariPeyvand Parhizkar RoudsariOsama KhattabAbdelrahman M AttiaPojsakorn DanpanichkulSoo Young HwangJessica S LiuTamar YaldaPin-Jung ChenJun GongCristina R FerroneNicole E RichNeehar D ParikhDavid J PinatoAmit G SingalJu Dong Yang

    Find these authors on Roon

    PD
    Dr. Pojsakorn Danpanichkul
    Primary Care · TTUHSC

    Summary

    INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly used in gastrointestinal and liver cancers. However, antibiotic-induced gut microbiota disruption may influence ICI effectiveness. The objective of this study was to evaluate association between antibiotic use and clinical outcomes among patients with gastrointestinal and liver cancers receiving ICI therapy.METHODS: In this meta-analysis, we searched studies involving adults with gastrointestinal or liver cancers treated with ICIs, comparing outcomes between patients with and without antibiotic use. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS), objective response rate, or disease control rate. Random-effects models were used for pooled analyses.RESULTS: Twenty-eight studies were included. Antibiotic use was associated with worse OS (HR 1.56; 95% CI: 1.23-1.98; I2 = 87.3%), PFS (HR 1.48; 95% CI: 1.15-1.90; I2 = 88.3%), and disease control rate (OR 0.55; 95% CI: 0.33-0.90; I2 = 65.0%), but no significant difference in objective response rate (OR 1.01; 95% CI: 0.78-1.31; I2 = 0%). Results were consistent in subgroup analyses by ICI type and timing of antibiotic administration. Antibiotic use was associated with worse OS and PFS in hepatocellular carcinoma (HR for OS: 1.49; 95% CI: 1.24-1.79; HR for PFS: 1.25; 95% CI: 1.01-1.56) and upper gastrointestinal cancers (HR for OS: 2.40; 95% CI: 1.48-3.90; HR for PFS: 2.15; 95% CI: 1.18-3.91), whereas colorectal cancer studies showed improved OS (HR: 0.58; 95% CI: 0.45-0.75).DISCUSSION: Antibiotic use is associated with worse outcomes in patients with gastrointestinal or liver cancer receiving ICIs and should be carefully justified. Prospective studies are needed to validate these results.
    PDDr. Pojsakorn Danpanichkul

    Dr. Pojsakorn Danpanichkul

    Internal Medicine · Primary Care
    Texas Tech University Health Sciences Center
    pojsakorn